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This case report describes an elderly patient with radioiodine-resistant differentiated
thyroid cancer and additional multiple metastases living in a rural setting, remote from
the specialist oncology service. This case is of interest because effective systemic
therapies for treatment-resistant cancers, such as lenvatinib, are now available but can
potentially cause significant toxicities that require extensive medical management. Here,
we discuss how patient care was provided collaboratively by the local community teams
integrated with remote specialist oncology services. A 77-year-old patient presented with
symptoms of cauda equina secondary to a large metastatic sacral deposit. The deposit
was biopsied, and histology revealed a diagnosis of differentiated follicular thyroid cancer
that was treated with external beam radiotherapy and thyroidectomy, followed by
radioiodine. However, the disease was found to be resistant to radioiodine therapy, and
the patient subsequently developed back pain due to new bone metastases. After further
palliative external beam radiotherapy, the patient was started on systemic treatment with
lenvatinib. Treatment has continued for more than 2.5 years with a slow but steady
improvement in symptoms and quality of life. Monitoring and assessment of lenvatinib
therapy and management of associated toxicities was coordinated remotely from a
specialist cancer center over 200 miles away, using the skills of the local medical and
nursing teams. This case report demonstrates how a cooperative effort using local teams
and video-conferencing links to a specialist cancer center can be applied to safely treat a
patient with a medication that may result in significant potential toxicities that require
attentive and dynamic management.
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Within the UK National Health Service, the oncological and
palliative care service system in the Highlands and Islands of
Scotland faces significant challenges due to the relatively sparse
population spread over a huge geographical area, and where
recruitment and retention of staff can be difficult (1). Here, with
patients expected to travel over greater distances to access
secondary healthcare, and with a limited set of available
services compared with the rest of the UK (2), much of the
day-to-day management of malignancy is coordinated locally
through primary care services.CASE DESCRIPTION
This case study provides details of a 77-year-old patient who
presented with features of cauda equina, and who had
subsequent diagnosis and management of metastatic
differentiated-type follicular thyroid cancer coordinated from
tertiary care centers more than 200 miles away from her home.
Thus, this patient’s case provides an interesting discussion of
patient-centered care within a challenging, resource-scarce,
environment. Further, this patient’s treatment with lenvatinib,
which shows promise for patients with radioiodine-resistant
differentiated thyroid cancer, has been safely managed through
coordinated care from local and specialist teams located a great
distance away. This case indicates that this rare cancer can be
treated remotely and safely with an agent with known toxicities
and adverse events that require close monitoring, without
requiring extensive travel by patients to clinics. However,
patients should be assessed on a case-by-case basis to
determine the feasibility of remote treatment.
At a follow-up appointment following an elective knee-joint
replacement in 2014, the patient presented with both urinaryFrontiers in Endocrinology | www.frontiersin.org 2and occasional fecal incontinence with associated back
pain (Figure 1). She had also experienced pain in her legs
and was concerned whether this was a complication of the
recent surgery. She reported depressed mood, poor sleep,
loss of appetite, and constant exhaustion. Past medical
history included a bowel obstruction, an inguinal hernia,
hypertension (treated with perindopril since mid-2012), and
mitral regurgitation.DIAGNOSTIC ASSESSMENT
The patient was admitted to a regional hospital in Inverness,
more than 100 miles away, for an X-ray and magnetic resonance
imaging scan of the spine, which showed a sacral mass of
9.0 cm x 4.7 cm x 4.0 cm encroaching on the S1–5 foramina as
the likely cause of symptoms (Figure 2). A computed
tomography (CT) scan of the chest, abdomen, and pelvis also
showed an enlarged thyroid gland. A biopsy of the sacral mass
led to a histological diagnosis of differentiated-type follicular
thyroid tumor, originating in a 4-cm mass in the right lobe of the
thyroid gland. After fine-needle aspiration biopsy, the mass was
graded THY4 (suspicious lesion).
Approximately 1 month following confirmation of the
diagnosis, the patient received external beam radiotherapy
(EBRT) (20 Gy in 4 fractions to the sacral area) for
symptomatic relief at a regional hospital in Inverness. The case
was discussed by the North of Scotland thyroid cancer
multidisciplinary team, who recommended the standard
treatment of thyroidectomy with subsequent radioiodine
therapy. As there was significant retrosternal extension of the
thyroid gland, the patient was transferred to the specialist thyroid
cancer team based in the university hospital in Aberdeen for a
radical thyroidectomy, as surgery required both the thoracic and
endocrine surgical teams to resect the thyroid gland. PathologyFIGURE 1 | Case Report Timeline: Patient was initially diagnosed in July 2014, and received EBRT, a radical thyroidectomy, and radioiodine therapy. Metastatic
bone tumors were found in January 2017 and the patient received additional EBRT. Seven months later the patient reported decreased quality of life and new
symptoms and began systemic treatment with lenvatinib. Adverse events and dose modifications were managed cooperatively between the local treatment team and
the specialist oncologist. As of April 2020, the patient remained stable, with an ECOG PS of 1. CT, computed tomography; EBRT, external beam radiotherapy;
ECOG PS, Eastern Cooperative Oncology Group performance status; QoL, quality of life.February 2021 | Volume 11 | Article 581014
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capsular invasion.
On recovery from surgery the patient had a course of
radioiodine treatment (3,750 MBq) in the university hospital in
Aberdeen that had a specialist thyroid cancer team. Iodine
uptake scanning following radioiodine treatment suggested
new focal uptake in the costochondral junction of the second
left rib, maxilla, mandible, soft tissue around the left lateral
border of the hyoid, and left anterior pelvis, in addition to the
known lesion in the sacrum. There was also some uptake of
radioiodine in the thyroid bed, which may have been due to
residual thyroid tissue. Failure to shrink the sacral mass meant
that the patient continued to experience complete urinary
incontinence. The patient had a urethral catheter sited, which
gave her the confidence to leave the house and improved her
quality of life; her Eastern Cooperative Oncology Group (ECOG)
performance status (PS) was 1 at this time.
Over the following year, the patient received a further 3
rounds of radioiodine therapy in Aberdeen (5,420 MBq in
March 2015; 5,710 MBq in July 2015; and 3,690 MBq in
November 2015), for a total radioiodine dose of 18.57 GBq.
On follow-up assessments through January 2016, the patient’s
thyroglobulin (Tg) levels decreased from 90,400 to 9,400 ng/ml,
but there was no reduction in the size of any of the tumor
deposits (Table 1). Between the third and fourth round of
radioiodine, the patient underwent colostomy surgery in the
regional hospital in Inverness because of ongoing fecal
incontinence. The urinary catheter and stoma resulted in
significant improvements in the patient’s physical and
emotional wellbeing, allowing her to perform activities of daily
living unaided (with an ECOG PS of 1).
Despite the appearance of metastases on imaging, the
patient’s mobility and clinical condition significantly improved
in the months following the final round of radioiodine, in
keeping with the improving Tg results. The patient was
prescribed levothyroxine to suppress thyroid-stimulating
hormone, and Tg levels decreased to 7,330 ng/ml between
November 2015 and June 2016 (Table 1).
The patient’s symptoms, imaging information, and blood test
results were regularly reviewed remotely by the regional North of
Scotland thyroid cancer multidisciplinary team. At a review ofFrontiers in Endocrinology | www.frontiersin.org 3the patient’s bone scans in January 2017, metastatic disease
progression was clinically determined and a trial period of
lenvatinib treatment was suggested by the multidisciplinary
team. The disease was suspected to be resistant to radioiodine
because of the relapse after a substantial total dose of radioiodine
that had been given in the prior year. A video-link consultation
was coordinated by a cancer specialist nurse between the
specialist oncologist, based in Aberdeen, and the patient, along
with a supportive friend. As the patient’s condition was stable
and her ECOG PS was still 1, it was agreed that continued
observation rather than additional treatment with lenvatinib was
appropriate at that time, given the possibility for adverse events
from a systemic treatment to impair quality of life for an
elderly patient.
In February 2017, the patient had further EBRT (8 Gy in one
fraction, covering the T8–T10 area) at the regional hospital in
Inverness. There was a good response to the EBRT, with the
patient remaining reasonably active and her Tg decreasing to
3,470 ng/ml by May 2017 (Table 1). In the summer of 2017, the
patient reported new symptoms of upper back and shoulder
pain, and CT imaging at the local hospital revealed new tumor
deposits in the thoracic spine, causing a compressive
radiculopathy, with further tumor deposits in the left ilium. In
keeping with this clinical progression, her Tg had significantly
increased to 119,200 ng/ml (Table 1). The patient received
additional radiotherapy (8 Gy in 1 fraction, covering the T3–
T5 area) in July 2017 at the regional hospital in Inverness and
was discharged with a reducing course of dexamethasone
(starting at 16 mg/day). Despite this treatment, the patient
experienced a reduction in mobility, with balance problems









Nov 2014 90,400 0.1 – Post-
thyroidectomy
Jan 2015 67,500 6.64 – Post 1st RAI
Apr 2015 25,004 2.04 71 Post 2nd RAI
Jan 2016 9,400 0.65 – Post 4th RAI
Jun 2016 7,330 0.06 – –
Oct 2016 8,071 0.09 – –
Feb 2017 5,802 0.02 – PD - palliative
radiotherapy
May 2017 3,470 0.04 – –
July 2017 – – – PD - further
radiotherapy
Aug 2017 119,200 0.02 – Lenvatinib
started
Sep 2017 132,300 0.13 – –
Nov 2017 10,493 0.43 66 –
Jan 2018 6,660 0.53 67 –
Oct 2018 10,451 11.27 67 –
Jan 2019 7,328 0.12 69 –
Mar 2019 8,246 0.08 68 –
May 2019 11,537 0.07 68 –
Jul 2019 16,372 0.11 69 –
Feb 2020 20,327 3.75 76 –February 2021 | Volume 11 |aThe normal range for thyroid-stimulating hormone is 0.34–5.4 mU/L.
RAI, radioactive iodine treatment; PD, progressive disease.Article 581014
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and required social support at home. At this point, the patient’s
ECOG PS was 3. The dose of dexamethasone was increased, due
to symptomatic burden, from a tapered-down dose of 4 mg/day
back to 8 mg/day. At a subsequent video-link consultation with
the specialist oncologist—based on the patient’s reduced
mobility, worsening ECOG PS, increased Tg levels, and
discovery of new tumor lesions—it was agreed that the patient
should start lenvatinib therapy.
Lenvatinib treatment began in August 2017 at a dose of
24 mg/day and the patient, together with a close friend and the
local cancer nurse specialist from a local hospital, joined a
video-link consultation every 2 weeks with the specialist
oncologist in Aberdeen. This planned close/frequent review
allowed for the detection and management of any significant
adverse events with lenvatinib treatment, and for appropriate
dose alterations of lenvatinib. Monitoring included blood
tests, weight, ECOG PS, and regular self-monitoring of
blood pressure.
Initially lenvatinib was well tolerated, with a grade 1 skin rash
and an increase in blood pressure that was treated with
amlodipine. However, by the end of cycle 1, the patient had
significant thrombocytopenia: her platelet count fell to 129/µL,
which was considered to be related to lenvatinib treatment
and the previous radiotherapy to the sacrum and thoracic
spine, both areas of significant bone marrow production. The
amlodipine dose was increased to 10 mg/day. Lenvatinib
treatment was paused for 2 weeks until platelet levels recovered
and was then restarted at a lower dose of 20 mg/day. However,
the patient’s platelet count decreased again, prompting a further
stepped-down dose reduction to lenvatinib 10 mg/day in
October 2017.
In November, after 3 months of lenvatinib therapy, a follow-
up CT scan was performed and reviewed at the local hospital and
found stable disease with no evidence of new tumor growth. The
patient’s Tg levels had initially increased from 119,200 ng/ml at
the start of the lenvatinib treatment to 132,300 ng/ml in
September 2017, but then declined to 10,493 ng/ml in
November 2017 (Table 1). As the patient’s symptoms were
stable, lenvatinib therapy was continued at 10 mg/day. Over
the next few months, the patient experienced a slow
but sustained improvement in mobility with an improved
ECOG PS of 2, as well as a significant reduction in analgesia
use. Her Tg levels also began to decrease (down to 6,660 ng/ml in
January 2018; Table 1). As treatment continued, the patient
regained sensation in her feet and became increasingly able
to move independently without the use of walking aids (ECOG
PS of 1).
In January 2018, the patient asked to increase the current dose
of lenvatinib to 14 mg/day, against the advice of the specialist
oncologist on the video-link consultation. The patient felt that
her adverse events were under control, with platelet levels
maintained above 100/µl, stable liver and renal function, and
stable blood pressure; she felt that a higher lenvatinib dose would
mean improved control of metastatic disease. However, the
increased dose of lenvatinib led to an increase in bloodFrontiers in Endocrinology | www.frontiersin.org 4pressure, requiring further changes to antihypertensive
medications (dose adjustments and the temporary addition of
bisoprolol). With the increase in antihypertensive medications
came metabolic disturbance, significant peripheral edema, and a
decrease in ECOG PS and quality of life. On the advice of the
specialist oncologist, via video-link consultation, the lenvatinib
dose was reduced back to 10 mg/day. With this change, the
patient’s antihypertensive medications were also reduced to
previous dose levels, and her condition improved to that
reported before the lenvatinib dose increase. Regular imaging
has shown neither deterioration of known sites of disease, nor
the appearance of new metastatic lesions.
In April 2020, some two and a half years after starting
lenvatinib, the patient’s Tg levels have increased steadily, to
20,357 ng/ml, but imaging scans indicate a generally stable
condition. Importantly, the patient’s ECOG PS has improved
from 3 (at the start of treatment with lenvatinib) to 1, and her
symptoms and analgesia requirements are stable. Indeed, the
patient has been well enough to attend family and cultural events
at many miles from home since 2018, although her mobility level
has deteriorated somewhat.DISCUSSION
Presentation of metastatic differentiated thyroid cancer as a
single sacral metastasis is uncommon (3). As this type of
cancer is often amenable to treatment (4), prompt diagnosis is
essential to optimize patient outcomes. Although diagnosis in
patients in rural areas may be more rapid than in urban
populations because of reduced wait times to see a doctor,
there are still significant challenges in the treatment and care
of a patient with a rare cancer living in a small rural community
at a great distance from a specialist cancer center (5–8). The
approach to the management and treatment of an elderly
person with radioiodine-resistant metastatic thyroid cancer
and limited mobility living in a small rural community, as
presented in this case report, raises several interesting points
for consideration.
Radioiodine-resistant metastatic differentiated thyroid cancer
is rare, and disease progression is variable (9). Some patients can
have slowly progressive disease, with little or no effect on the
patient’s quality of life for some time, while others can exhibit
rapid progression and the need to commence systemic treatment
(10). This systemic treatment can cause significant toxicity and
requires initial frequent monitoring and assessment by a
multidisciplinary team familiar with the treatment options
(currently [as of April 2020], either lenvatinib or sorafenib) (9,
11). This poses a challenge for health services responsible for
small populations spread over a large and rugged geographical
area. Similar challenging rural environments for patients with
rare cancers requiring specialist oversight occur throughout the
world. The patient in this report lived over 200 miles from the
specialist thyroid cancer regional center in Aberdeen and
travelling from home would require either a flight of 45
minutes, or a 4.5–5-hour drive time each way for at least 16February 2021 | Volume 11 | Article 581014
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substantial disruption to the patient’s daily life. However, the use
of video-conferencing with the specialist oncologist, and most
importantly collaboration with not only the local cancer nursing
team but also the patient’s general practitioner (GP), enabled
successful management of the patient’s adverse events and,
ultimately, stabilized the disease.
Although there can be significant challenges with staffing
levels in small, remote, rural communities, the staff who work
there are typically dedicated and keen to do what is best for their
patients. They are used to not having specialist staff close at hand,
and are willing to employ a remote, multidisciplinary approach
to patient care. For this patient, the team consisted of the
specialist based in Aberdeen, the local cancer nursing
specialists, the local GP, staff in the local district hospital (for
CT scanning), and oncology staff in the regional hospital in
Inverness serving the patient’s locality. The cancer nurse
specialist (or the deputy when the cancer nurse specialist was
unavailable) was the critical link in coordinating the patient’s
care and monitoring toxicity. These nurses not only have
training in palliative care but also in the treatment of patients
with systemic oncology therapies, with some procedures being
delivered in the local hospital. This mixture of skills makes
cancer nurse specialists well placed to be involved in the care
of patients with rarer cancers. Additional training was provided to
the nurses by Eisai, the manufacturers of lenvatinib. The success in
this case is due to the collaborative approach of a number of
clinicians working together with a motivated and well-informed
patient. Clear communication among the members of this small
team was critical to successful remote management of this patient
and might be more difficult with larger teams.
Rural living alters patient access, and perhaps attitudes, to
care (5, 6), and the need to travel for treatment may alter
decisions to undergo certain therapies. It has been recognized
that rural patients tend to have poorer outcomes, and in some
cases present to their GP with more advanced disease (6),
although this is not necessarily always the case (7). It is
important that rural patients do not miss out on newer
therapies that could be administered locally, despite the
challenges of a remote location, by employing techniques such
as coordinated remote care, using video-conferencing for
example, with the staff in the specialist centers.
In this case, later presentation may have had an impact on the
extent of disease at diagnosis and response to initial treatments.
Lenvatinib, as an oral therapy, offered a good opportunity for
further treatment of the patient at home, despite the refractory
nature of her widespread disease to usual treatments.
Coordination of care by the remote cancer specialist via the
locally based cancer nursing specialist and the patient’s GP, asFrontiers in Endocrinology | www.frontiersin.org 5demonstrated in this case, can reduce the need for patients to
travel long distances (12). However, this situation may require
further education of the care providers involved with regard to
newer treatments to ensure best outcomes (12).
The challenge of managing rare diseases in rural locations is
an area of medicine not yet widely researched, with low volumes
of evidence being produced. Therefore, this is an area with
potential for further research as increasing numbers of new,
targeted treatments emerge for patients with cancer who present
with more-disseminated and treatment-resistant disease.DATA AVAILABILITY STATEMENT
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